MX2010006025A - Analogo de pterina para tratar afeccion sensible a bh4. - Google Patents
Analogo de pterina para tratar afeccion sensible a bh4.Info
- Publication number
- MX2010006025A MX2010006025A MX2010006025A MX2010006025A MX2010006025A MX 2010006025 A MX2010006025 A MX 2010006025A MX 2010006025 A MX2010006025 A MX 2010006025A MX 2010006025 A MX2010006025 A MX 2010006025A MX 2010006025 A MX2010006025 A MX 2010006025A
- Authority
- MX
- Mexico
- Prior art keywords
- treating
- tetrahydrobiopterin
- analog
- responsive condition
- pterin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se dan a conocer en este documento análogos de tetrahidrobiopterina, composiciones que contienen los mismos y métodos para tratar a un individuo que sufre de una afección sensible a la tetrahidrobiopterina mediante la administración del análogo. Estos análogos se contemplan para el uso dondequiera que la tetrahidrobiopterina se utiliza actualmente para tratar afecciones sensibles a las terapias de tetrahidrobipterina.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1873508P | 2008-01-03 | 2008-01-03 | |
US1975308P | 2008-01-08 | 2008-01-08 | |
PCT/US2008/069319 WO2009088530A1 (en) | 2008-01-03 | 2008-07-07 | Pterin analog for treating bh4 responsive condition |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010006025A true MX2010006025A (es) | 2010-06-30 |
Family
ID=39765023
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010006025A MX2010006025A (es) | 2008-01-03 | 2008-07-07 | Analogo de pterina para tratar afeccion sensible a bh4. |
Country Status (11)
Country | Link |
---|---|
US (2) | US7601717B2 (es) |
EP (1) | EP2224927B1 (es) |
JP (1) | JP2011508775A (es) |
CN (1) | CN101969953B (es) |
AU (1) | AU2008347005B2 (es) |
BR (1) | BRPI0821970A2 (es) |
CA (1) | CA2711160A1 (es) |
ES (1) | ES2524026T3 (es) |
MX (1) | MX2010006025A (es) |
RU (1) | RU2470642C2 (es) |
WO (1) | WO2009088530A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2008206486C1 (en) * | 2007-01-12 | 2013-09-26 | Biomarin Pharmaceutical Inc. | Tetrahydrobiopterin prodrugs |
JP5066756B2 (ja) * | 2010-04-22 | 2012-11-07 | 学校法人日本大学 | 脳機能障害予防・改善用の薬剤及び飲食物 |
US20130338176A1 (en) * | 2010-10-29 | 2013-12-19 | The Trustees Of Columbia University In The City Of New York | Methods of preventing and treating hyperlipidemia or atherosclerosis |
CN103988080B (zh) * | 2011-10-11 | 2016-06-08 | 加利福尼亚大学董事会 | 用于腹主动脉瘤的生物标记物 |
PL2806877T3 (pl) | 2012-01-23 | 2020-06-01 | Sage Therapeutics, Inc. | Formulacje neuroaktywnego steroidu zawierające kompleks allopregnanolonu i eteru sulfobutylowego beta-cyklodekstryny |
KR102259938B1 (ko) * | 2012-11-14 | 2021-06-03 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | 폐동맥 고혈압 및 폐 손상의 치료에 이용하기 위한 1,3-디히드로이미다졸-2-티온 유도체 |
BR112017013608B8 (pt) * | 2014-12-30 | 2022-08-23 | Dow Agrosciences Llc | Picolinamidas como fungicidas |
MA43815A (fr) | 2016-03-08 | 2021-04-07 | Sage Therapeutics Inc | Stéroïdes neuroactifs, compositions, et leurs utilisations |
AU2018254556B2 (en) * | 2017-04-21 | 2024-05-02 | Steven Hoffman | Compositions and methods for treating retinopathy |
WO2019067782A1 (en) * | 2017-09-28 | 2019-04-04 | University Of Massachusetts | COMBINED TREATMENT OF NEUROPSYCHIATRIC DISORDERS |
WO2019175328A1 (en) | 2018-03-14 | 2019-09-19 | Imba - Institut Für Molekulare Biotechnologie Gmbh | Bh4pathwayactivationandusethereoffortreatingcancer |
WO2019175332A1 (en) | 2018-03-14 | 2019-09-19 | Imba - Institut Für Molekulare Biotechnologie Gmbh | Bh4 pathway inhibition and use thereof for treating t-cell mediated autoimmune diseases or hypersensitivity |
JP2020068734A (ja) * | 2018-11-01 | 2020-05-07 | 国立大学法人東京工業大学 | Sprをコードするポリヌクレオチドを含む組換えベクター、及びそれを含む組成物 |
CN112394178B (zh) * | 2020-11-16 | 2022-08-05 | 首都医科大学附属北京朝阳医院 | 莫西沙星相关肝损伤的生物标志物、试剂盒及应用 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2601215A (en) | 1948-03-17 | 1952-06-17 | American Cyanamid Co | Process of preparing dihydropterins |
US3505329A (en) | 1968-02-06 | 1970-04-07 | Smithkline Corp | Process for the synthesis of biopterin |
JPS5883691A (ja) | 1981-11-13 | 1983-05-19 | Kanegafuchi Chem Ind Co Ltd | 1′,2′−ジアシル−(6r,s)−5,6,7,8−テトラヒドロ−l−ビオプテリンおよびその製法 |
CH651755A5 (en) | 1982-03-03 | 1985-10-15 | Kanegafuchi Chemical Ind | Use of pterin derivatives |
JPS5925323A (ja) * | 1982-03-03 | 1984-02-09 | 鐘淵化学工業株式会社 | プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤 |
GB8318833D0 (en) | 1983-07-12 | 1983-08-10 | Wellcome Found | Chemical compounds |
JPS5976086A (ja) | 1982-09-20 | 1984-04-28 | ザ ウエルカム フアウンデ−シヨン リミテツド | プテリジン化合物 |
JPS59112987A (ja) * | 1982-12-20 | 1984-06-29 | Kanegafuchi Chem Ind Co Ltd | 1′,2′―ジアシル―(6r,s)―5,6,7,8―テトラヒドロ―l―ビオプテリンおよびその製法 |
US5196533A (en) | 1983-04-11 | 1993-03-23 | South Alabama Medical Science Foundation, Usa | Cyclization of 5 amino-pyrimidines to quinoid 6,6 disubstituted dihydropteridines |
US4587340A (en) | 1983-09-19 | 1986-05-06 | Burroughs Wellcome Co. | Biopterin analogs |
JPS60178887A (ja) | 1984-02-23 | 1985-09-12 | Kanegafuchi Chem Ind Co Ltd | 5,6,7,8−テトラヒドロ−l−ビオプテリンの製造法 |
JPS60199889A (ja) | 1984-03-24 | 1985-10-09 | Kanegafuchi Chem Ind Co Ltd | 5,6,7,8−テトラヒドロ−l−エリスロ−ビオプテリンの硫酸塩およびその製法 |
US4550109A (en) | 1984-05-31 | 1985-10-29 | The Board Of Regents, The University Of Texas System | Lipoidal biopterin compounds |
JPS617287A (ja) | 1984-06-21 | 1986-01-13 | Kanegafuchi Chem Ind Co Ltd | 5‐デオキシ‐l‐アラビノースの製造法 |
US4713454A (en) | 1985-01-28 | 1987-12-15 | Shiratori Pharmaceutical Co., Ltd. | Preparation process of (6R)-tetrahydro-L-biopterin |
JPS61277618A (ja) | 1985-06-04 | 1986-12-08 | Suntory Ltd | 自閉症治療剤 |
DE3520896A1 (de) * | 1985-06-11 | 1986-12-11 | Wolfgang Prof. Dr.Dr.h.c. 7750 Konstanz Pfleiderer | Neue pterin-derivate und diese enthaltende arzneimittel |
JPS61293983A (ja) | 1985-06-22 | 1986-12-24 | Kanegafuchi Chem Ind Co Ltd | 5n−アシルテトラヒドロプテリン化合物 |
GB8719367D0 (en) | 1987-08-15 | 1987-09-23 | Wellcome Found | Therapeutic compounds |
US4937342A (en) | 1987-11-30 | 1990-06-26 | Kabushiki Kaisha Vitamin Kenkyusyo | Intermediates for synthesizing BH4 and its derivatives |
JP2575781B2 (ja) | 1988-02-29 | 1997-01-29 | 日清製粉株式会社 | 2,3−ジアシルオキシ−4−ヒドロキシ−トペンタナールおよびその製造方法 |
EP0375329B1 (en) | 1988-12-19 | 1995-05-31 | The Wellcome Foundation Limited | Antiviral pyrimidine and purine compounds, process for their preparation and pharmaceutical compositions containing them |
US5198547A (en) | 1992-03-16 | 1993-03-30 | South Alabama Medical Science Foundation, Usa | Process for N5-formylating tetrahydropteridines |
DE4308739C1 (de) | 1993-03-19 | 1994-06-23 | Henning Berlin Gmbh | Pterinderivate, ihre Herstellung und ihre Verwendung |
DE4418097A1 (de) | 1994-05-24 | 1995-11-30 | Cassella Ag | Verwendung von Tetrahydropteridin-Derivaten als Hemmstoffe der NO-Synthase |
US5753656A (en) * | 1994-08-05 | 1998-05-19 | Suntory Limited | Method for treating spinocerebellar degeneration |
WO1998004558A1 (fr) | 1996-07-31 | 1998-02-05 | Artemis, Inc. | Piegeurs d'oxygene actifs a base de derives de pterine |
WO1998008516A1 (fr) * | 1996-08-30 | 1998-03-05 | Suntory Limited | Preparations servant a la prevention et au traitement de maladies provoquees par une hypofonction de l'oxyde nitrique synthase |
JP4306825B2 (ja) | 1998-02-27 | 2009-08-05 | アスビオファーマ株式会社 | インスリン抵抗性が関与する血管機能異常を伴う疾患の予防または治療剤 |
DE19944767A1 (de) | 1999-09-17 | 2001-03-29 | Vasopharm Biotech Gmbh & Co Kg | N-substituierte 4-Aminopteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
AU2001280215B9 (en) | 2000-08-31 | 2007-03-22 | Asubio Pharma Co., Ltd. | Process for Production of Biopterin Compound |
US20030078231A1 (en) | 2001-06-22 | 2003-04-24 | Wilburn Michael D. | Orthomolecular sulpho-adenosylmethionine derivatives with antioxidant properties |
DE10260263A1 (de) * | 2002-12-20 | 2004-07-15 | Biocrates Life Sciences Gmbh | Verwendung von Tetrahydrobiopterinderivaten zur Behandlung und Ernährung von Patienten mit Aminosäurestoffwechselstörungen |
WO2005037286A1 (en) * | 2003-03-25 | 2005-04-28 | Vasopharm Biotech Gmbh | Use of pteridine derivatives for the treatment of increased intracranial pressure and secondary ischemia |
US20070167353A1 (en) | 2003-10-24 | 2007-07-19 | John Hilfinger | Prodrug composition |
US20050137141A1 (en) | 2003-10-24 | 2005-06-23 | John Hilfinger | Prodrug composition |
DK1708690T3 (en) | 2003-11-17 | 2016-11-07 | Biomarin Pharm Inc | TREATMENT OF PHENYLKETONURI WITH BH4 |
EP1776364A2 (en) | 2003-11-17 | 2007-04-25 | BioMarin Pharmaceutical Inc. | Processes for preparing tetrahydrobiopterin, and analogs of tetrahydrobiopterin |
US7067659B2 (en) | 2004-04-23 | 2006-06-27 | Duke University | Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof |
JP2008504295A (ja) | 2004-06-25 | 2008-02-14 | ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システム | 注意欠陥多動性障害及び高フェニルアラニン血症の治療のための方法及び組成物 |
EP2436379A1 (en) | 2004-11-17 | 2012-04-04 | BioMarin Pharmaceutical Inc. | Stable tablet formulation |
EP1819340A2 (en) | 2004-12-08 | 2007-08-22 | Biomarin Pharmaceutical Inc. | Methods and compositions for the treatment of pulmonary hypertension of the newborn |
US20060194800A1 (en) | 2005-01-07 | 2006-08-31 | University Of Strathclyde | Pteridine derivatives as nitric oxide synthase activators |
US20060194808A1 (en) * | 2005-01-14 | 2006-08-31 | Chronorx Llc, An Alaska Limited Liability Company | Clinical applications of tetrahydrobiopterin, lipoic acid and their salts and methods of preparing tetrahydrobiopterin bis-lipoate |
WO2007067570A1 (en) | 2005-12-05 | 2007-06-14 | Biomarin Pharmaceutical Inc. | Methods and compositions for the treatment of disease |
AU2008206486C1 (en) | 2007-01-12 | 2013-09-26 | Biomarin Pharmaceutical Inc. | Tetrahydrobiopterin prodrugs |
-
2008
- 2008-07-07 BR BRPI0821970-2A patent/BRPI0821970A2/pt not_active Application Discontinuation
- 2008-07-07 AU AU2008347005A patent/AU2008347005B2/en not_active Ceased
- 2008-07-07 JP JP2010541450A patent/JP2011508775A/ja not_active Ceased
- 2008-07-07 CA CA2711160A patent/CA2711160A1/en not_active Abandoned
- 2008-07-07 CN CN2008801242617A patent/CN101969953B/zh not_active Expired - Fee Related
- 2008-07-07 MX MX2010006025A patent/MX2010006025A/es active IP Right Grant
- 2008-07-07 WO PCT/US2008/069319 patent/WO2009088530A1/en active Application Filing
- 2008-07-07 ES ES08781435.6T patent/ES2524026T3/es active Active
- 2008-07-07 EP EP08781435.6A patent/EP2224927B1/en not_active Not-in-force
- 2008-07-07 RU RU2010132278/04A patent/RU2470642C2/ru active
- 2008-10-29 US US12/260,855 patent/US7601717B2/en not_active Expired - Fee Related
-
2009
- 2009-10-12 US US12/577,680 patent/US8324210B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US7601717B2 (en) | 2009-10-13 |
CN101969953B (zh) | 2013-01-09 |
WO2009088530A1 (en) | 2009-07-16 |
CN101969953A (zh) | 2011-02-09 |
US8324210B2 (en) | 2012-12-04 |
EP2224927B1 (en) | 2014-08-20 |
JP2011508775A (ja) | 2011-03-17 |
ES2524026T3 (es) | 2014-12-03 |
AU2008347005B2 (en) | 2013-10-03 |
RU2010132278A (ru) | 2012-02-10 |
RU2470642C2 (ru) | 2012-12-27 |
CA2711160A1 (en) | 2009-07-16 |
EP2224927A1 (en) | 2010-09-08 |
AU2008347005A1 (en) | 2009-07-16 |
US20090176790A1 (en) | 2009-07-09 |
BRPI0821970A2 (pt) | 2015-06-23 |
US20100093742A1 (en) | 2010-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010006025A (es) | Analogo de pterina para tratar afeccion sensible a bh4. | |
WO2008089008A3 (en) | Tetrahydrobiopterin prodrugs | |
AU2018236800B2 (en) | DNA-PK inhibitors | |
MX338707B (es) | Compuestos heterociclicos activadores de proteina cinasa activada por 5'-amp (ampk) y metodos para emplearlos. | |
MX347917B (es) | Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso. | |
MX2016003863A (es) | Nuevos derivados de 3-(1h-pirazol-4-il)-1h-pirrolo[2,3-c]piridina como inhibidores de la cinasa inductora de nf-kappab. | |
PH12016501160A1 (en) | Isochromene derivatives as phosphoinositide 3-kinases inhibitors | |
MD4371C1 (ro) | Derivaţi de benzo[f][1,4]oxazepin-5-one ca modulatori ai canalelor ionice | |
PH12014501900A1 (en) | Oxazolidin-2-one compounds and uses thereof as pi3ks inhibitors | |
TN2012000578A1 (en) | Tetrahydro-pyrido-pyrimidine derivatives | |
EA201201193A1 (ru) | Тиенопиримидины, содержащие гетероциклоалкил, предназначенные для фармацевтических композиций | |
MX2012009073A (es) | Derivados de 1, 2, 4-triazin-4-amina. | |
EA201300556A1 (ru) | Аминоспиртзамещенные производные 2,3-дигидроимидазо[1,2-с] хиназолина, пригодные для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом | |
GEP20166474B (en) | Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors | |
MX2012004078A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119. | |
NZ627361A (en) | 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors | |
MX2009009154A (es) | Derivados de espiro-pirano-pirazol. | |
MX2011006006A (es) | Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos. | |
MX2011009493A (es) | Compuestos para el tratamiento de trastornos metabolicos. | |
WO2012065110A3 (en) | S-protected cysteine analogs and related compounds | |
GEP20156315B (en) | Oxazoline and isoxazoline derivatives as crac modulators | |
MX2014000964A (es) | Derivados aza heterociclicos sustituidos. | |
MX2011007639A (es) | Compuestos de carboxamida y metodos para usar los mismos. | |
MX2013002162A (es) | Metodos para tratar la intoxicacion con alcohol, transtornos debido al consumo de alcohol y alcolismo que comprenden la administracion de dihidromiricetina. | |
MX342119B (es) | 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |